An accident in AstraZeneca's trial is leading the company to seek a change in its US trial to pursue a 90% efficacious vaccine.

A quick breakdown of what we learned yesterday, what to expect going forward. $AZNhttps://t.co/KJK0fRyM93

— Anjalee Khemlani (@AnjKhem) November 24, 2020

Super proud of our team.. AstraZeneca has the least vaccine experience of the front-runners racing to deliver a Covid-19 shot. But it has promised the world the most doses. https://t.co/TRFhDzN4qE

— Menelas Pangalos (@MenePangalos) November 24, 2020

"AstraZeneca plans to supply every region of the world by 2022 without profiting directly from the vaccine during the pandemic. Working in partnership with the University of Oxford, the company is pricing the vaccine at $3 to $5 a dose."https://t.co/2dir72bdWx?

— Aisehman | Darurat = Mudarat (@Aisehman) November 24, 2020